SOTIO Doses First Patient in AURELIO-05 Phase 2 Trial of Nanrilkefusp Alfa in Combination with Cetuximab
January 19, 2023 08:00 ET
|
SOTIO Biotech
BASEL, Jan. 19, 2023 (GLOBE NEWSWIRE) -- SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that the first patient was dosed in its Phase 2 AURELIO-05...
SOTIO Exercises Option for Novel Antibody-Drug Conjugate Program under Agreement with LegoChem Biosciences
November 29, 2022 08:00 ET
|
SOTIO Biotech
SOT106 is an antibody-drug conjugate (ADC) targeting an attractive surface antigen expressed on multiple solid tumorsPreclinical efficacy and tolerability studies of SOT106 show promising results...
SOTIO Presents Preclinical Data from BOXR CAR-T Program and Trial Design of Phase 2 AURELIO-04 Study at SITC Annual Meeting
November 10, 2022 08:00 ET
|
SOTIO Biotech
Findings on the mechanism of action from the BOXR CAR-T platform indicate improved metabolic function and preservation of early memory subsets of T cells SOTIO anticipates initiating first-in-human...
SOTIO to Present the AURELIO-04 Phase 2 Study Design and Findings from BOXR Research at the SITC Annual Meeting
October 18, 2022 08:00 ET
|
SOTIO Biotech
BASEL, Switzerland and CAMBRIDGE, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that it will share two poster...
SOTIO Bolsters Leadership Team with Appointment of Martin Steegmaier as Chief Scientific Officer
September 14, 2022 08:00 ET
|
SOTIO Biotech
PRAGUE, Czech Republic, Sept. 14, 2022 (GLOBE NEWSWIRE) -- SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced the appointment of Martin Steegmaier, Ph.D., MBA, as...
SOTIO Strengthens Management Team with Appointment of Robyn Hunter as Chief Financial Officer
September 12, 2022 08:00 ET
|
SOTIO Biotech
CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announces the appointment of Robyn Hunter as chief financial officer....
SOTIO Doses First Patient in AURELIO-04 Phase 2 Trial of SOT101 in Combination with KEYTRUDA® (pembrolizumab)
July 26, 2022 08:30 ET
|
SOTIO Biotech
AURELIO-04 will enroll up to 320 patients and test the combination in multiple solid tumor indicationsClinical collaborator, MSD (Merck & Co., Inc., Rahway, NJ, USA), will supply KEYTRUDA for the...
Data from SOTIO’s Phase 1/1b AURELIO-03 Trial of SOT101 Demonstrate Clinical Benefit in Patients with Solid Tumors
May 26, 2022 17:00 ET
|
SOTIO Biotech
Data demonstrate that SOT101 monotherapy and SOT101 in combination with pembrolizumab have a favorable safety profileEncouraging efficacy signals were observed for both SOT101 monotherapy and SOT101...
Oral Presentation of Interim Data from the AURELIO-03 Study of SOT101 at the 2022 ASCO Annual Meeting
April 27, 2022 10:00 ET
|
SOTIO Biotech
SOTIO will share interim safety and efficacy results from SOTIO’s AURELIO-03 study on Saturday, June 4AURELIO-03 is a Phase 1/1b dose escalation study of the interleukin-15 superagonist SOT101 as...
SOTIO Initiates CLAUDIO-01 Trial with Antibody-Drug Conjugate SOT102 in Patients with Gastric and Pancreatic Cancer
April 26, 2022 08:00 ET
|
SOTIO Biotech
CLAUDIO-01 is the first-in-human trial of SOT102, a CLDN18.2 (Claudin 18.2) targeting antibody-drug conjugate (ADC)The trial will enroll up to 109 patients with gastric and pancreatic cancer PRAGUE,...